Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Small-Cell Lung Cancer to Oncology Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 26
In Progress Trials by Phase 27
Clinical Trials by Trial Status 28
Clinical Trials by End Point Status 30
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Small-Cell Lung Cancer Therapeutics Clinical Trials 35
Prominent Drugs 37
Latest Clinical Trials News on Small-Cell Lung Cancer 38
Jul 13, 2018: The Lancet Oncology jourl chooses a PharmaMar poster as one of the most relevant of the ASCO 2018 congress 38
Jun 25, 2018: Genentech’s TECENTRIQ in Combition with Chemotherapy Helped People with Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy 38
Jun 12, 2018: PharmaMar requests the modification from primary endpoint to OS for the ATLANTIS trial 38
Jun 11, 2018: PARP inhibitor improves overall response rates in small cell lung cancer patients 39
Jun 04, 2018: PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018 40
Jun 04, 2018: Tarveda Therapeutics Announces Results from Phase 1 Study of PEN-221 Presented at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting 40
May 29, 2018: Positive recommendation of IDMC to Zepsyre to continue the Phase III trial with in small-cell lung cancer (ATLANTIS) 41
May 21, 2018: Ascentage Pharma Announces Promising Phase 1 Interim Results Of APG-1252 At 2018 ASCO Annual Meeting 41
Clinical Trial Profile Spshots 42
Appendix 574
Abbreviations 574
Definitions 574
Research Methodology 575
Secondary Research 575
About GlobalData 575
Contact Us 576
Disclaimer 576
Source 576